

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/546,857	04/10/2000	Brian C. Cunningham	P1734R1	3105
23552	7590 07/22/2004		EXAM	INER
MERCHAN'	Γ & GOULD PC		SPECTOR, I	ORRAINE
P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903			ART UNIT	PAPER NUMBER
MINNERIOE	30, 14114 33 102 0703		1647	
			DATE MAILED: 07/22/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/546,857	CUNNINGHAM ET AL.			
Office Action Summary	Examiner	Art Unit			
	Lorraine Spector, Ph.D.	1647			
The MAILING DATE of this communication a		h the correspondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a ref. If NO period for reply is specified above, the maximum statutory perions Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	1. 1.136(a). In no event, however, may a repepty within the statutory minimum of thirty will apply and will expire SIX (6) MONT ute, cause the application to become ABA	ply be timely filed (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on 21	May 2004.				
	nis action is non-final.				
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D.	11, 453 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>20-23 and 25-56</u> is/are pending in t	he application.				
4a) Of the above claim(s) is/are withdr					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>20-23 and 25-56</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and	or election requirement.				
Application Papers					
9) The specification is objected to by the Examir	ner.				
10) The drawing(s) filed on is/are: a) a		y the Examiner.			
Applicant may not request that any objection to the	•				
Replacement drawing sheet(s) including the corre	ection is required if the drawing(s	s) is objected to. See 37 CFR 1.121(d).			
11)☐ The oath or declaration is objected to by the	Examiner. Note the attached	Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume	nts have been received. nts have been received in Ap	oplication No			
Copies of the certified copies of the pr	•	eceived in this National Stage			
application from the International Bure	, ,,,				
* See the attached detailed Office action for a list	st of the certified copies not r	eceived.			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Si	ummary (PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)	/Mail Date			
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	8) 5) Notice of Inf 6) Other:	formal Patent Application (PTO-152) 			

Application/Control Number: 09/546,857

Art Unit: 1647

Part III: Detailed Office Action

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/21/2004 has been entered.

Claims 20-23 and 25-56 are pending and under consideration.

Formal Matters:

The objection to claim 28 has been overcome by applicants amendment.

Objections and Rejections under 35 U.S.C. §112:

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 20-23 and 25-56 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

The claims have been amended to indicate that they are drawn to VEGF variants comprising substitutions "at residues corresponding to" particular amino acid residues of human VEGF. As stated in the previous rejection under 35 U.S.C. §112, second paragraph, it is variants of human VEGF that are the subject of the invention. There is no disclosure in the specification as originally filed that variants of other VEGF orthologs are envisioned, nor is language indicating that substitutions are to be at positions corresponding to, rather than at, the recited positions. Accordingly, the claim language,

Art Unit: 1647

rather than clearly indicating that the claims are drawn to the disclosed variants of human VEGF, have been broadened substantially, beyond the scope of the original disclosure.

Conclusion:

No claim is allowed.

The claims are free of the prior art.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Lorraine M. Spector. Dr. Spector can normally be reached Monday through Friday, 9:00 A.M. to 3:00 P.M. Effective 1/21/2004, Dr. Spector's telephone number is 571-272-0893.

If attempts to reach the Examiner by telephone are unsuccessful, please contact the Examiner's supervisor, Ms. Brenda Brumback, at telephone number 571-272-0961.

Certain papers related to this application may be submitted to Group 1800 by facsimile transmission The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Official papers filed by fax should be directed to (703) 872-9306 (before final rejection) or (703)872-9307 (after final). Faxed draft or informal communications with the examiner should be directed to 571-273-0893.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. information for unpublished applications is available through Private PAIR only. more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Lorraine Spector, Ph.D.

Primary Examiner

Application/Control Number: 09/546,857

Art Unit: 1647

09/546857.3 7/19/2004